- AbbVie has raised its forecast for the full-year 2025 adjusted earnings per share (EPS) to a range of $12.09 to $12.29, up from the previous estimate of $11.99 to $12.19.
- The updated EPS forecast is based on the current trade environment, excluding any potential changes in trade policies or new tariffs affecting the pharmaceutical industry.
- In the first quarter, AbbVie’s net revenue rose to $13.34 billion, an 8.4% increase year over year, surpassing the expected $12.92 billion.
- Adjusted EPS for the first quarter stood at $2.46, compared to last year’s $2.31.
- Revenue from key products included:
- Humira: $1.12 billion, below the expected $1.32 billion.
- Skyrizi: $3.43 billion, ahead of the $3.2 billion estimate.
- Rinvoq: $1.72 billion, exceeding the $1.58 billion forecast.
- Imbruvica: $738 million, surpassing the $688.8 million estimate.
- Venclexta: $665 million, higher than the $630.7 million estimate.
- Botox – Cosmetic: $556 million, below the anticipated $592 million.
- Juvederm: $231 million, less than the $259.7 million estimate.
- Botox – Therapeutic: $866 million, above the $799.6 million forecast.
- Vraylar: $765 million, surpassing the $734.9 million estimate.
- Ubrelvy: $240 million, ahead of the $231 million projection.
- The first quarter results included an unfavorable impact of $0.13 per share due to acquired in-process research and development (IPR&D) and milestones expense.
- The guidance for EPS does not account for the impact related to AbbVie’s licensing agreement with Gubra to develop GUB014295, as this transaction closed after the first quarter.
Abbvie Inc on Smartkarma
Analysts at Baptista Research on Smartkarma have been closely following AbbVie Inc and recently published insightful reports on the company’s performance. One report titled “AbbVie Inc.: An Analysis Of Its Immunology Market Expansion, Oncology Pipeline & ADC Strategy!” highlighted AbbVie’s robust performance in 2024, despite challenges like competition affecting Humira sales. With a total revenue of $56.3 billion, exceeding initial guidance, and adjusted earnings per share at $10.12, AbbVie’s “ex-Humira” platform, including Skyrizi and Rinvoq, showed significant growth.
In another report by Baptista Research, “AbbVie Inc.: The SKYRIZI & RINVOQ Revolution: Capturing Market Share with Game-Changing Therapies! – Major Drivers,” analysts commended AbbVie’s strong third-quarter results in 2024 driven by the success of SKYRIZI and RINVOQ. The company’s diversified portfolio exceeded sales forecasts by $260 million, showcasing robust mid-single-digit operational sales growth. Projections suggest a combined sales figure of over $17 billion for the year, surpassing initial estimates by $1.3 billion, underlining the impact of these innovative therapies on AbbVie’s performance in the market.
A look at Abbvie Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 2 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Abbvie Inc. has received a positive overall outlook based on the Smartkarma Smart Scores. With strong scores in Dividend and Momentum, the company is expected to provide consistent returns to investors while showing good market performance. Additionally, Abbvie has demonstrated resilience in the face of challenges, reflecting its ability to adapt and remain stable in various market conditions. However, there is room for improvement in the areas of Value and Growth, which could enhance the company’s long-term prospects.
Abbvie Inc. is a pharmaceutical company specializing in research and development of products for various therapeutic areas including immunology, oncology, and neuroscience. With a focus on producing pharmaceutical drugs for specialty diseases such as Hepatitis C and Multiple Sclerosis, Abbvie aims to address critical health issues impacting individuals worldwide. Despite facing challenges, the company’s strong performance in dividend payments and market momentum suggest a promising trajectory for its long-term success.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
